ClinicalTrials.gg
TerminatedNCT03379051Updated Aug 22, 2022

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

A Phase 1/2 interventional study of Venetoclax and Umbralisib in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by TG Therapeutics, Inc.. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-22.

Sponsored by TG Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Strategic/Business Decision

From the registry’s dates

  • Primary completion was May 2022, 4 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by TG Therapeutics, Inc. — none open to participants now, none under way, none of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · TG Therapeutics, Inc..

Enrollment
9th of 18
78 · median 72
Started
2018
with 1 other
Phase 1/2
3 of 18
none open now
Registered
14th of 18
by date

Among the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by TG Therapeutics, Inc., this one is the 9th largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 1/2, and was the 14th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by TG Therapeutics, Inc. is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by TG Therapeutics, Inc. as a file.
02

Study summary

Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia, or Non-Hodgkin's Lymphoma
  • to or relapsed after at least 1 prior treatment regimen
  • (ECOG) score of 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Any major surgery, chemotherapy or immunotherapy within the last 21 days
  • Known virus, virus or infection
  • Known histological transformation from CLL to an aggressive lymphoma (Richter's)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Ublituximab + Umbralisib + Venetoclax

    Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Venetoclax oral daily dose

    Drug: Venetoclax · Drug: Umbralisib · Biological: Ublituximab

  • Experimental
    Ublituximab + Umbralisib + Lenalidomide

    Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions; Umbralisib and Lenalidomide both administered days 1 - 21 of every 28 days

    Drug: Umbralisib · Biological: Ublituximab · Drug: Lenalidomide

Interventions

  • BCL-2 Inhibitor

    Also known as: Venclexta

  • PI3K-Delta Inhibitor

    Also known as: TGR-1202

  • BiologicalUblituximab

    Glycoengineered Anti-CD20 mAb

    Also known as: TG-1101

  • Thalidomide Analog, immunomodulatory agent with antiangiogenic and antineoplastic properties

    Also known as: Revlimid

06

What researchers measure

Primary outcomes

  1. Determine Acceptable Adverse Events That Are Related to Treatment

    Time frame: 12 months

Secondary outcomes

  1. Overall Response and Complete Remission Rate

    Time frame: 12 months

  2. Minimum Residual Disease (MRD)

    Time frame: 12 months

07

Study locations

3 sites
  • TG Therapeutics Investigational Trial Site
    Chicago, Illinois 60611, United States
  • TG Therapeutics Investigational Trial Site
    Rochester, New York 14642, United States
  • TG Therapeutics Investigational Trial Site
    Cleveland, Ohio 44195, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in May 2022, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2017
First posted
Dec 20, 2017
StartActual
Mar 27, 2018
Primary completionActual
May 26, 2022
CompletionActual
Jun 16, 2022
Last update
Aug 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03379051
Collaborators
James P. Wilmot Cancer Center
Responsible party
Sponsor
First posted
Dec 20, 2017
Start date
Mar 27, 2018
Primary completion
May 26, 2022
Completion
Jun 16, 2022
Last update
Aug 22, 2022

Study contacts

Paul Barr, MD
study chair · Wilmot Cancer Institute - University of Rochester

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion